Pozen to buy Tribute and move to Ireland
This article was originally published in Scrip
Executive Summary
Pozen, which a week ago announced the immediate retirement of its founder, chairman and CEO John Plachetka, is to acquire Tribute Pharmaceuticals Canada for $146m. On completion, slated for the end of 2015, the combined company will be named Aralez Pharmaceuticals and be domiciled in Ireland.